(R)-3,4-DCPG

Pricing Availability Delivery Time Qty
Cat.No. 1395 - (R)-3,4-DCPG | C10H9NO6 | CAS No. 201730-10-1
Description: AMPA antagonist/weak NMDA antagonist
Chemical Name: (R)-3,4-Dicarboxyphenylglycine
Purity: ≥96% (HPLC)
Datasheet
Citations (1)
Literature

Biological Activity

AMPA receptor antagonist with weak activity at NMDA receptors and little activity at kainate receptors. (RS)-3,4-DCPG (Cat. No. 1394) and (S)-3,4-DCPG (Cat. No. 1302) also available.

Technical Data

M. Wt 239.18
Formula C10H9NO6
Storage Desiccate at RT
Purity ≥96% (HPLC)
CAS Number 201730-10-1
PubChem ID 6604849
InChI Key IJVMOGKBEVRBPP-SSDOTTSWSA-N
Smiles N[C@@]([H])(C(O)=O)C1=CC(C(O)=O)=C(C(O)=O)C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

SolubilitySoluble to 100 mM in water

Preparing Stock Solutions

The following data is based on the product molecular weight 239.18. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 4.18 mL 20.9 mL 41.81 mL
5 mM 0.84 mL 4.18 mL 8.36 mL
10 mM 0.42 mL 2.09 mL 4.18 mL
50 mM 0.08 mL 0.42 mL 0.84 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:
Safety Datasheet

References

References are publications that support the products' biological activity.

Moldrich et al (2001) Anticonvulsant activity of 3,4-dicarboxyphenylglycines in DBA/2 mice. Neuropharmacology 40 732 PMID: 11311902

Thomas et al (1997) Dicarboxyphenylglycines antagonize AMPA- but not kainate-induced depolarizations in neonatal rat motoneurones. Eur.J.Pharmacol. 338 111 PMID: 9455991


If you know of a relevant reference for (R)-3,4-DCPG, please let us know.

View Related Products by Product Action

View all Non-selective Ionotropic Glutamate Antagonists

Keywords: (R)-3,4-DCPG, supplier, AMPA, antagonists, weak, NMDA, Glutamate, Ionotropic, Non-Selective, iGlur, Receptors, Non-selective, Ionotropic, Glutamate, Non-selective, Ionotropic, Glutamate, Tocris Bioscience

1 Citation for (R)-3,4-DCPG

Citations are publications that use Tocris products. Selected citations for (R)-3,4-DCPG include:

Sun et al (2012) Structure based model for the prediction of phospholipidosis induction potential of small molecules. J Chem Inf Model 52 1798 PMID: 22725677


Do you know of a great paper that uses (R)-3,4-DCPG from Tocris? If so please let us know.

Commented out for usability testing

Reviews

TODO: Add Reviews

Literature in this Area

Pain

Pain Research Product Guide

A collection of over 250 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Pain

Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Pathways for (R)-3,4-DCPG

Protocols

TODO: Add Protocols